Table 5.
Effect of miltefosine alone or combined with benznidazole at different sub-therapeutic or additive regimes on parasite burden at the end of the treatment in BALB/cJ mice infected with Trypanosoma cruzi (VD strain).
| Treatment(mg/kg/day) | n | +FBE | qPCR | |||||
|---|---|---|---|---|---|---|---|---|
| +Blood after CYP | Parasite Eq/mL blood | +BloodbeforeCYP | ParasiteEq/mL | +SkeletalMuscle | +CardiacMuscle | |||
| Subtherapeutic regime | ||||||||
| MLT (25) | 4 | 4/4 | 4/4 | 4.099 ( ± 4.240) | ND | ND | ND | ND |
| BZ (5) | 4 | 4/4 | 4/4 | 2.856 ( ± 2.275) | ND | ND | ND | ND |
| MLT (25) + BZ (5) | 4 | 4/4 | 4/4 | 1.553 ( ± 2.154) | ND | ND | ND | ND |
| NT | 1 | 1/1 | 1/1 | 163.734 | ND | ND | ND | ND |
| Additive regime* | ||||||||
| BZ (100) | 8 | 1/8 | 2/8 (2*) | NQ | 3/8 (3*) | NQ | 5/8 (1*) | 4/8 (1*) |
| MLT (50) + BZ (50) | 8 | 0/8 | 0/8 | NQ | 1/8 (1*) | NQ | 4/8 (1*) | 3/8 (2*) |
MLT, miltefosine. BZ, benznidazole. NT, infected non-treated. CYP, cyclophosphamide (200 mg/kg; ip).
+FBE, positive parasitemia result in fresh blood examination at the end of the treatment.
+SkM, positive result for qPCR assay in skeletal muscle.
+CM, positive result for qPCR assay in cardiac muscle.
NQ, not quantifiable sample.
ND, not determined.
*Includes positive but not quantifiable samples.